Bacterial conjunctivitis: Current aspects of diagnosis and therapy

Die bakterielle Bindehautentzundung gehort mit einer Inzidenz von 135:10000 in den Vereinigten Staaten von Amerika zu den haufigsten Krankheitsbildern der Augenheilkunde. Obwohl viele Falle selbstlimitierend sind, kann sie zu Komplikationen fuhren oder eine antibiotische Therapie erfordern. Dieser Beitrag fasst relevante Aspekte zu Epidemiologie, Erregern, Diagnose und Behandlungsoptionen zusammen. Abstract Bacterial conjunctivitis is a leading cause of infectious conjunctivitis in children and second most common cause in adults. Although often self-limiting, it can lead to complications like corneal scarring and systemic infections in high-risk groups including newborns and immunocompromised patients. Thus, prompt diagnosis and treatment are essential for these vulnerable populations. Common bacterial causes are Staphylococcus aureus and Streptococcus pneumoniae in adults and Haemophilus influenzae and Moraxella catarrhalis in children. Clinical features alone do not reliably identify the causative pathogen. Microbiological testing is necessary for persistent or severe cases. Topical antibiotics like azithromycin or fluorochinolones are usually prescribed. However, gonococcal and chlamydial conjunctivitis warrant systemic antibiotics due to their potential for severe complications. Increasing antibiotic resistance might even necessitate tailored therapy based on antibiotic susceptibility profiles. Screening and treating pregnant women is an effective prevention strategy by reducing perinatal transmission (especially of gonococcal and chlamydial infections). In summary, while often self-limiting, potential complications and rising antibiotic resistance underscore the importance of timely diagnosis and treatment of bacterial conjunctivitis. Preventive measures including maternal screening are crucial public health initiatives to curb the risks associated with this common eye infection.